CDKN2A mutation
|
Triple Negative Breast Cancer
|
CDKN2A mutation
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
CDKN2A mutation
|
Breast Cancer
|
CDKN2A mutation
|
Breast Cancer
|
ribociclib Resistant: B - Late Trials
|
ribociclib Resistant: B - Late Trials
|
CDKN2A mutation
|
Gallbladder Cancer
|
CDKN2A mutation
|
Gallbladder Cancer
|
palbociclib Resistant: C3 – Early Trials
|
palbociclib Resistant: C3 – Early Trials
|
CDKN2A mutation
|
Clear Cell Renal Cell Carcinoma
|
CDKN2A mutation
|
Clear Cell Renal Cell Carcinoma
|
palbociclib Sensitive: C3 – Early Trials
|
palbociclib Sensitive: C3 – Early Trials
|
CDKN2A mutation
|
Pancreatic Cancer
|
CDKN2A mutation
|
Pancreatic Cancer
|
palbociclib Resistant: C3 – Early Trials
|
palbociclib Resistant: C3 – Early Trials
|
CDKN2A mutation
|
Solid Tumor
|
CDKN2A mutation
|
Solid Tumor
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
CDKN2A mutation
|
Melanoma
|
CDKN2A mutation
|
Melanoma
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
CDKN2A mutation
|
Urothelial Cancer
|
CDKN2A mutation
|
Urothelial Cancer
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
CDKN2A mutation
|
Biliary Tract Cancer
|
CDKN2A mutation
|
Biliary Tract Cancer
|
toripalimab Resistant: C3 – Early Trials
|
toripalimab Resistant: C3 – Early Trials
|
CDKN2A mutation
|
NSCLC
|
CDKN2A mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
CDKN2A mutation
|
Penile Cancer
|
CDKN2A mutation
|
Penile Cancer
|
nivolumab Sensitive: C4 – Case Studies
|
nivolumab Sensitive: C4 – Case Studies
|
CDKN2A mutation
|
SCCHN
|
CDKN2A mutation
|
SCCHN
|
AZD1775 + VIC-1911 Sensitive: D – Preclinical
|
AZD1775 + VIC-1911 Sensitive: D – Preclinical
|
CDKN2A mutation
|
NSCLC
|
CDKN2A mutation
|
NSCLC
|
AZD1775 + VIC-1911 Sensitive: D – Preclinical
|
AZD1775 + VIC-1911 Sensitive: D – Preclinical
|
CDKN2A mutation
|
Melanoma
|
CDKN2A mutation
|
Melanoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|